Pterostilbene

Name: Pterostilbene
Brand: MedChemExpress
SKU: HY-N0828
Rating: 5.0 (10 reviews)

Cat. No.: HY-N0828 Pureté: 99.89%: Fiche technique
COA

SDS
Instruction de manipulation
FAQs
Technical Support

Pterostilbene is a stilbenoid isolated from blueberries and Pterocarpus marsupium. Shows anti-oxidant, anti-inflammatory, anti-carcinogenic, anti-diabetic and anti-obesity properties. Pterostilbene blocks ROS production, also exhibits inhibitory activity against various free radicals such as DPPH, ABTS, hydroxyl, superoxide and hydrogen peroxide.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

CAS No. : 537-42-8

Size	Stock	Quantité
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	En stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	En stock	Estimated Time of Arrival: December 31
Solid
25 mg	En stock	Estimated Time of Arrival: December 31
50 mg	En stock	Estimated Time of Arrival: December 31
100 mg	En stock	Estimated Time of Arrival: December 31
500 mg	En stock	Estimated Time of Arrival: December 31
1 g	En stock	Estimated Time of Arrival: December 31
5 g	En stock	Estimated Time of Arrival: December 31
10 g	En stock	Estimated Time of Arrival: December 31
50 g	Obtenir un devis

or Bulk Inquiry

* Veuillez sélectionner la quantité avant d'ajouter des articles.

This product is a controlled substance and not for sale in your territory.

Avis client

Based on 10 publication(s) in Google Scholar

Other Forms of Pterostilbene:

Pterostilbene (Standard) In-stock

10 Publications Citing Use of MCE Pterostilbene

Cell Imaging/Staining

RT-PCR

In Vivo Efficacy Study

: Pterostilbene purchased from MedChemExpress. Usage Cited in: Phytother Res. 2025 Apr 16. [Abstract]; Cell morphology of EV-A71- and EV-D68-infected cells treated with Pterostilbene (Pte) (20 and 40 μM; 48 h) or Resveratrol (Res) under a phase-contrast microscope. Pterostilbene (Pte) treatment was significantly better than Resveratrol (Res) in protecting RD cells from EV-A71 and EV-D68 infection.

: Pterostilbene purchased from MedChemExpress. Usage Cited in: Phytother Res. 2025 Apr 16. [Abstract]; RD cells were infected with EV-A71 or EV-D68 at an MOI of 0.1 for 1 h, and then cells were treated with Pterostilbene (Pte) (10-40 μM; 24 h). The levels of viral RNA were quantified using RT-PCR.

: Pterostilbene purchased from MedChemExpress. Usage Cited in: Phytother Res. 2025 Apr 16. [Abstract]; The protein levels of VP1 were detected using western blot analysis. RD cells were infected with EV-A71 at an MOI of 0.1, 0.2, and 0.5 for 1 h, and then the cells were treated with Pterostilbene (Pte) (20 μM; 24 h). Pterostilbene (Pte) treatment downregulated the levels of VP1 protein.

: Pterostilbene purchased from MedChemExpress. Usage Cited in: Phytother Res. 2025 Apr 16. [Abstract]; RD cells were mock-infected or infected with EV-A71 at a MOI of 0.1 for 1 h, and then cells were treated with Pterostilbene (Pte) (5-20 μM; 24 h). Pterostilbene (Pte) reduced synthesis of VP1 protein for EV-A71.

: Pterostilbene purchased from MedChemExpress. Usage Cited in: Phytother Res. 2025 Apr 16. [Abstract]; Pterostilbene (Pte) (50 mg/kg; once daily; i.g.; 7 d) markedly improved survival rate of mice and alleviated clinical signs of EV-A71 infection.

: Pterostilbene purchased from MedChemExpress. Usage Cited in: Arch Biochem Biophys. 2023 Apr:738:109561. [Abstract]; Pterostilbene (20 μM; 6 h) can reverse the changes of ferroptosis-related proteins in OGCs (COV434 and KGN cells) induced by H₂O₂. Pterostilbene significantly increases the expression of GPX4 while decreases the expression of ACSL4.

Recommandations en vedette

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Activité biologique
Pureté et documentation
Références
Avis client

Description

Pterostilbene is a stilbenoid isolated from blueberries and Pterocarpus marsupium^[1]. Shows anti-oxidant, anti-inflammatory, anti-carcinogenic, anti-diabetic and anti-obesity properties^[1]^[4]. Pterostilbene blocks ROS production^[3], also exhibits inhibitory activity against various free radicals such as DPPH, ABTS, hydroxyl, superoxide and hydrogen peroxide^[4].

Cellular Effect

Cell Line	Type	Value	Description	References
518A2	IC₅₀	17.39 87 Compound: 21	Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay	[PMID: 22749392]
518A2	IC₅₀	17.39 3 Compound: 21	Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay	[PMID: 22749392]
518A2	IC₅₀	17.39 3 Compound: 21	Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay	[PMID: 22749392]
A253 cell line	IC₅₀	17.33 87 Compound: 21	Cytotoxicity against human A253 cells after 96 hrs by SRB assay Cytotoxicity against human A253 cells after 96 hrs by SRB assay	[PMID: 22749392]
A253 cell line	IC₅₀	17.33 3 Compound: 21	Cytotoxicity against human A253 cells after 96 hrs by SRB assay Cytotoxicity against human A253 cells after 96 hrs by SRB assay	[PMID: 22749392]
A2780	IC₅₀	15.56 87 Compound: 21	Cytotoxicity against human A2780 cells after 96 hrs by SRB assay Cytotoxicity against human A2780 cells after 96 hrs by SRB assay	[PMID: 22749392]
A2780	IC₅₀	15.56 3 Compound: 21	Cytotoxicity against human A2780 cells after 96 hrs by SRB assay Cytotoxicity against human A2780 cells after 96 hrs by SRB assay	[PMID: 22749392]
A2780	IC₅₀	15.56 3 Compound: 21	Cytotoxicity against human A2780 cells after 96 hrs by SRB assay Cytotoxicity against human A2780 cells after 96 hrs by SRB assay	[PMID: 22749392]
A549	IC₅₀	71.7 3 Compound: 6	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 19689125]
A549	IC₅₀	15.86 3 Compound: 21	Cytotoxicity against human A549 cells after 96 hrs by SRB assay Cytotoxicity against human A549 cells after 96 hrs by SRB assay	[PMID: 22749392]
A549	IC₅₀	15.86 87 Compound: 21	Cytotoxicity against human A549 cells after 96 hrs by SRB assay Cytotoxicity against human A549 cells after 96 hrs by SRB assay	[PMID: 22749392]
A549	IC₅₀	26 3 Compound: Pter	Cytotoxicity against human A549 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
A549	IC₅₀	15.86 3 Compound: 21	Cytotoxicity against human A549 cells after 96 hrs by SRB assay Cytotoxicity against human A549 cells after 96 hrs by SRB assay	[PMID: 22749392]
A549	IC₅₀	26 3 Compound: Pter	Cytotoxicity against human A549 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
A549	IC₅₀	71.7 3 Compound: 6	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 19689125]
B16-BL6	IC₅₀	15.9 3 Compound: 6	Cytotoxicity against mouse B16-BL6 cells after 72 hrs by MTT assay Cytotoxicity against mouse B16-BL6 cells after 72 hrs by MTT assay	[PMID: 19689125]
B16-BL6	IC₅₀	15.9 3 Compound: 6	Cytotoxicity against mouse B16-BL6 cells after 72 hrs by MTT assay Cytotoxicity against mouse B16-BL6 cells after 72 hrs by MTT assay	[PMID: 19689125]
A549	IC₅₀	26 3 Compound: Pter	Cytotoxicity against human A549 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
A549	IC₅₀	71.7 3 Compound: 6	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 19689125]
BXPC-3	GI₅₀	6.5 6 Compound: 14d	In vitro growth inhibition of BXPC-3 (human pancreatic adenocarcinoma) cell line. In vitro growth inhibition of BXPC-3 (human pancreatic adenocarcinoma) cell line.	[PMID: 12036362]
BXPC-3	IC₅₀	31 3 Compound: Pter	Cytotoxicity against human BxPC3 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human BxPC3 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
BXPC-3	IC₅₀	31 3 Compound: Pter	Cytotoxicity against human BxPC3 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human BxPC3 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
Caco-2	IC₅₀	14.46 3 Compound: 16, Pterostilbene	Cytotoxicity against human Caco-2 cells after 3 days by [3H]thymidine incorporation assay Cytotoxicity against human Caco-2 cells after 3 days by [3H]thymidine incorporation assay	[PMID: 20627379]
B16-BL6	IC₅₀	15.9 3 Compound: 6	Cytotoxicity against mouse B16-BL6 cells after 72 hrs by MTT assay Cytotoxicity against mouse B16-BL6 cells after 72 hrs by MTT assay	[PMID: 19689125]
Caco-2	IC₅₀	14.46 3 Compound: 16, Pterostilbene	Cytotoxicity against human Caco-2 cells after 3 days by [3H]thymidine incorporation assay Cytotoxicity against human Caco-2 cells after 3 days by [3H]thymidine incorporation assay	[PMID: 20627379]
COLO 201	IC₅₀	29 3 Compound: Pter	Cytotoxicity against human COLO201 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human COLO201 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
COLO 201	IC₅₀	29 3 Compound: Pter	Cytotoxicity against human COLO201 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human COLO201 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
BXPC-3	GI₅₀	6.5 6 Compound: 14d	In vitro growth inhibition of BXPC-3 (human pancreatic adenocarcinoma) cell line. In vitro growth inhibition of BXPC-3 (human pancreatic adenocarcinoma) cell line.	[PMID: 12036362]
DLD-1	IC₅₀	16.45 3 Compound: 21	Cytotoxicity against human DLD1 cells after 96 hrs by SRB assay Cytotoxicity against human DLD1 cells after 96 hrs by SRB assay	[PMID: 22749392]
BXPC-3	IC₅₀	31 3 Compound: Pter	Cytotoxicity against human BxPC3 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human BxPC3 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
DLD-1	IC₅₀	16.45 87 Compound: 21	Cytotoxicity against human DLD1 cells after 96 hrs by SRB assay Cytotoxicity against human DLD1 cells after 96 hrs by SRB assay	[PMID: 22749392]
DU-145	GI₅₀	4.3 6 Compound: 14d	The concentration causing 50% reduction in the net protein increase (cell growth inhibition, GI50) against central nervous system (CNS) SF-268 cells The concentration causing 50% reduction in the net protein increase (cell growth inhibition, GI50) against central nervous system (CNS) SF-268 cells	[PMID: 12036362]
HCT-116	IC₅₀	> 60 3 Compound: 2	Cytotoxicity against human HCT116 cells assessed as inhibition of cell growth after 24 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as inhibition of cell growth after 24 hrs by MTT assay	[PMID: 26204233]
DU-145	GI₅₀	2.7 6 Compound: 14d	In vitro growth inhibition of DU-145 (human prostate carcinoma) cell line. In vitro growth inhibition of DU-145 (human prostate carcinoma) cell line.	[PMID: 12036362]
DU-145	GI₅₀	4.3 6 Compound: 14d	The concentration causing 50% reduction in the net protein increase (cell growth inhibition, GI50) against central nervous system (CNS) SF-268 cells The concentration causing 50% reduction in the net protein increase (cell growth inhibition, GI50) against central nervous system (CNS) SF-268 cells	[PMID: 12036362]
HCT-116	IC₅₀	34.08 3 Compound: PTE	Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 34043359]
COLO 201	IC₅₀	29 3 Compound: Pter	Cytotoxicity against human COLO201 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human COLO201 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
Caco-2	IC₅₀	14.46 3 Compound: 16, Pterostilbene	Cytotoxicity against human Caco-2 cells after 3 days by [3H]thymidine incorporation assay Cytotoxicity against human Caco-2 cells after 3 days by [3H]thymidine incorporation assay	[PMID: 20627379]
HCT-116	IC₅₀	>60 3 Compound: 2	Cytotoxicity against human HCT116 cells assessed as inhibition of cell growth after 24 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as inhibition of cell growth after 24 hrs by MTT assay	[PMID: 26204233]
HEK293	IC₅₀	19.5 3 Compound: 1H6	Inhibition of TNFalpha induced NF-kappaB activation in human 293 cells after 24 hrs by luciferase reporter gene assay Inhibition of TNFalpha induced NF-kappaB activation in human 293 cells after 24 hrs by luciferase reporter gene assay	[PMID: 18487053]
DLD-1	IC₅₀	16.45 3 Compound: 21	Cytotoxicity against human DLD1 cells after 96 hrs by SRB assay Cytotoxicity against human DLD1 cells after 96 hrs by SRB assay	[PMID: 22749392]
HCT-116	IC₅₀	34.08 3 Compound: PTE	Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 34043359]
HeLa	IC₅₀	9.43 3 Compound: 6	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay Cytotoxicity against human HeLa cells after 72 hrs by MTT assay	[PMID: 19689125]
HEK293	EC₅₀	3.6 3 Compound: 7	Agonist activity at rat TRPA1 expressed in HEK293 cells assessed as induction of intracellular calcium level Agonist activity at rat TRPA1 expressed in HEK293 cells assessed as induction of intracellular calcium level	[PMID: 26750258]
DU-145	GI₅₀	2.7 6 Compound: 14d	In vitro growth inhibition of DU-145 (human prostate carcinoma) cell line. In vitro growth inhibition of DU-145 (human prostate carcinoma) cell line.	[PMID: 12036362]
HT-1080	IC₅₀	93.4 3 Compound: 6	Cytotoxicity against human HT1080 cells after 72 hrs by MTT assay Cytotoxicity against human HT1080 cells after 72 hrs by MTT assay	[PMID: 19689125]
HEK293	IC₅₀	>10 3 Compound: 7	Antagonist activity at human TRPV1 expressed in HEK293 cells assessed as inhibition of allyl isothiocyanate-induced increase of intracellular calcium level Antagonist activity at human TRPV1 expressed in HEK293 cells assessed as inhibition of allyl isothiocyanate-induced increase of intracellular calcium level	[PMID: 26750258]
HT-29	IC₅₀	> 60 3 Compound: 2	Cytotoxicity against human HT-29 cells assessed as inhibition of cell growth after 24 hrs by MTT assay Cytotoxicity against human HT-29 cells assessed as inhibition of cell growth after 24 hrs by MTT assay	[PMID: 26204233]
DU-145	GI₅₀	4.3 6 Compound: 14d	The concentration causing 50% reduction in the net protein increase (cell growth inhibition, GI50) against central nervous system (CNS) SF-268 cells The concentration causing 50% reduction in the net protein increase (cell growth inhibition, GI50) against central nervous system (CNS) SF-268 cells	[PMID: 12036362]
HEK293	IC₅₀	7.5 3 Compound: 7	Antagonist activity at rat TRPA1 expressed in HEK293 cells assessed as inhibition of allyl isothiocyanate-induced increase of intracellular calcium level Antagonist activity at rat TRPA1 expressed in HEK293 cells assessed as inhibition of allyl isothiocyanate-induced increase of intracellular calcium level	[PMID: 26750258]
HT-29	IC₅₀	23.8 3 Compound: 16, Pterostilbene	Cytotoxicity against human HT-29 cells after 3 days by [3H]thymidine incorporation assay Cytotoxicity against human HT-29 cells after 3 days by [3H]thymidine incorporation assay	[PMID: 20627379]
HEK293	IC₅₀	19.5 3 Compound: 1H6	Inhibition of TNFalpha induced NF-kappaB activation in human 293 cells after 24 hrs by luciferase reporter gene assay Inhibition of TNFalpha induced NF-kappaB activation in human 293 cells after 24 hrs by luciferase reporter gene assay	[PMID: 18487053]
HT-29	IC₅₀	28 3 Compound: Pter	Cytotoxicity against human HT-29 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human HT-29 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
HCT-116	IC₅₀	34.08 3 Compound: PTE	Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 34043359]
HeLa	IC₅₀	9.43 3 Compound: 6	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay Cytotoxicity against human HeLa cells after 72 hrs by MTT assay	[PMID: 19689125]
J774	IC₅₀	10.5 3 Compound: 4	Antiinflammatory activity in mouse J774 cells assessed as reduction in LPS-induced MCP1 expression after 24 hrs by ELISA Antiinflammatory activity in mouse J774 cells assessed as reduction in LPS-induced MCP1 expression after 24 hrs by ELISA	[PMID: 29726680]
HCT-116	IC₅₀	34.08 3 Compound: PTE	Antiproliferative activity against human HCT-116 cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human HCT-116 cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay	[PMID: 38964169]
HL-60	IC₅₀	35 3 Compound: 2a, pterostilbene	Antiproliferative activity against human HL60 cell line Antiproliferative activity against human HL60 cell line	[PMID: 16686543]
J774	IC₅₀	16.7 3 Compound: 4	Antiinflammatory activity in mouse J774 cells assessed as reduction in LPS-induced nitric oxide production after 24 hrs by Griess assay Antiinflammatory activity in mouse J774 cells assessed as reduction in LPS-induced nitric oxide production after 24 hrs by Griess assay	[PMID: 29726680]
HL-60	IC₅₀	35 3 Compound: 12a	In vitro inhibitory concentration against proliferation of HL60 cells In vitro inhibitory concentration against proliferation of HL60 cells	[PMID: 12877593]
HCT-116	IC₅₀	> 60 3 Compound: 2	Cytotoxicity against human HCT116 cells assessed as inhibition of cell growth after 24 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as inhibition of cell growth after 24 hrs by MTT assay	[PMID: 26204233]
J774	IC₅₀	8.7 3 Compound: 4	Antiinflammatory activity in mouse J774 cells assessed as reduction in LPS-induced IL6 expression after 24 hrs by ELISA Antiinflammatory activity in mouse J774 cells assessed as reduction in LPS-induced IL6 expression after 24 hrs by ELISA	[PMID: 29726680]
HT-1080	IC₅₀	93.4 3 Compound: 6	Cytotoxicity against human HT1080 cells after 72 hrs by MTT assay Cytotoxicity against human HT1080 cells after 72 hrs by MTT assay	[PMID: 19689125]
L02	IC₅₀	> 100 3 Compound: Pter	Cytotoxicity against human L-02 cells incubated for 24 hrs by MTT assay Cytotoxicity against human L-02 cells incubated for 24 hrs by MTT assay	[PMID: 34506712]
HEK293	EC₅₀	3.6 3 Compound: 7	Agonist activity at rat TRPA1 expressed in HEK293 cells assessed as induction of intracellular calcium level Agonist activity at rat TRPA1 expressed in HEK293 cells assessed as induction of intracellular calcium level	[PMID: 26750258]
LN-229	IC₅₀	14 3 Compound: Pter	Cytotoxicity against human LN229 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human LN229 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
HT-29	IC₅₀	23.8 3 Compound: 16, Pterostilbene	Cytotoxicity against human HT-29 cells after 3 days by [3H]thymidine incorporation assay Cytotoxicity against human HT-29 cells after 3 days by [3H]thymidine incorporation assay	[PMID: 20627379]
HT-29	IC₅₀	28 3 Compound: Pter	Cytotoxicity against human HT-29 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human HT-29 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
MCF7	IC₅₀	14.11 3 Compound: 21	Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay	[PMID: 22749392]
HEK293	IC₅₀	19.5 3 Compound: 1H6	Inhibition of TNFalpha induced NF-kappaB activation in human 293 cells after 24 hrs by luciferase reporter gene assay Inhibition of TNFalpha induced NF-kappaB activation in human 293 cells after 24 hrs by luciferase reporter gene assay	[PMID: 18487053]
HT-29	IC₅₀	>60 3 Compound: 2	Cytotoxicity against human HT-29 cells assessed as inhibition of cell growth after 24 hrs by MTT assay Cytotoxicity against human HT-29 cells assessed as inhibition of cell growth after 24 hrs by MTT assay	[PMID: 26204233]
MCF7	IC₅₀	65 3 Compound: Pterostlibene	Cytotoxicity against human MCF7 cells measured 24 hrs by MTT assay Cytotoxicity against human MCF7 cells measured 24 hrs by MTT assay	[PMID: 27598238]
MDA-MB-231	IC₅₀	31.17 3 Compound: PTE	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 34043359]
J774	IC₅₀	8.7 3 Compound: 4	Antiinflammatory activity in mouse J774 cells assessed as reduction in LPS-induced IL6 expression after 24 hrs by ELISA Antiinflammatory activity in mouse J774 cells assessed as reduction in LPS-induced IL6 expression after 24 hrs by ELISA	[PMID: 29726680]
HEK293	IC₅₀	7.5 3 Compound: 7	Antagonist activity at rat TRPA1 expressed in HEK293 cells assessed as inhibition of allyl isothiocyanate-induced increase of intracellular calcium level Antagonist activity at rat TRPA1 expressed in HEK293 cells assessed as inhibition of allyl isothiocyanate-induced increase of intracellular calcium level	[PMID: 26750258]
HEK293	IC₅₀	> 10 3 Compound: 7	Antagonist activity at human TRPV1 expressed in HEK293 cells assessed as inhibition of allyl isothiocyanate-induced increase of intracellular calcium level Antagonist activity at human TRPV1 expressed in HEK293 cells assessed as inhibition of allyl isothiocyanate-induced increase of intracellular calcium level	[PMID: 26750258]
J774	IC₅₀	10.5 3 Compound: 4	Antiinflammatory activity in mouse J774 cells assessed as reduction in LPS-induced MCP1 expression after 24 hrs by ELISA Antiinflammatory activity in mouse J774 cells assessed as reduction in LPS-induced MCP1 expression after 24 hrs by ELISA	[PMID: 29726680]
MDA-MB-231	IC₅₀	63 3 Compound: Pter	Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
J774	IC₅₀	16.7 3 Compound: 4	Antiinflammatory activity in mouse J774 cells assessed as reduction in LPS-induced nitric oxide production after 24 hrs by Griess assay Antiinflammatory activity in mouse J774 cells assessed as reduction in LPS-induced nitric oxide production after 24 hrs by Griess assay	[PMID: 29726680]
NCI-H460	IC₅₀	17 3 Compound: Pter	Cytotoxicity against human NCI-H460 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human NCI-H460 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
NIH3T3	IC₅₀	12.19 3 Compound: 21	Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay	[PMID: 22749392]
K562	IC₅₀	10 3 Compound: 2a, pterostilbene	Antiproliferative activity against human K562 cell line expressing Bcr-Abl Antiproliferative activity against human K562 cell line expressing Bcr-Abl	[PMID: 16686543]
KM-20L2	GI₅₀	3.4 6 Compound: 14d	In vitro growth inhibition of KM20L2 cell line. In vitro growth inhibition of KM20L2 cell line.	[PMID: 12036362]
NIH3T3	IC₅₀	12.2 3 Compound: 16	Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by sulforhodamine-B colorimetric assay Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by sulforhodamine-B colorimetric assay	[PMID: 21803587]
HL-60	IC₅₀	35 3 Compound: 12a	In vitro inhibitory concentration against proliferation of HL60 cells In vitro inhibitory concentration against proliferation of HL60 cells	[PMID: 12877593]
HL-60	IC₅₀	35 3 Compound: 2a, pterostilbene	Antiproliferative activity against human HL60 cell line Antiproliferative activity against human HL60 cell line	[PMID: 16686543]
L02	IC₅₀	>100 3 Compound: Pter	Cytotoxicity against human L-02 cells incubated for 24 hrs by MTT assay Cytotoxicity against human L-02 cells incubated for 24 hrs by MTT assay	[PMID: 34506712]
PANC-1	IC₅₀	50 3 Compound: Pter	Cytotoxicity against human PANC1 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human PANC1 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
HT-1080	IC₅₀	93.4 3 Compound: 6	Cytotoxicity against human HT1080 cells after 72 hrs by MTT assay Cytotoxicity against human HT1080 cells after 72 hrs by MTT assay	[PMID: 19689125]
RAW264.7	IC₅₀	30 3 Compound: 1b	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS/IFNgamma-induced NO production by measuring NO level preincubated for 2 hrs and followed by LPS/IFNgamma addition and measured after 24 hrs by Griess assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS/IFNgamma-induced NO production by measuring NO level preincubated for 2 hrs and followed by LPS/IFNgamma addition and measured after 24 hrs by Griess assay	[PMID: 31350127]
LN-229	IC₅₀	14 3 Compound: Pter	Cytotoxicity against human LN229 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human LN229 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
MCF7	GI₅₀	2.3 6 Compound: 14d	Cell growth inhibition of breast MCF-7 cells, expressed as 50% reduction in the net protein increase Cell growth inhibition of breast MCF-7 cells, expressed as 50% reduction in the net protein increase	[PMID: 12036362]
SK-MEL-2	IC₅₀	17 3 Compound: Pter	Cytotoxicity against human SK-MEL-2 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human SK-MEL-2 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
T47D	IC₅₀	35 3 Compound: Pter	Cytotoxicity against human T47D cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human T47D cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
MCF7	IC₅₀	14.11 87 Compound: 21	Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay	[PMID: 22749392]
HT-29	IC₅₀	23.8 3 Compound: 16, Pterostilbene	Cytotoxicity against human HT-29 cells after 3 days by [3H]thymidine incorporation assay Cytotoxicity against human HT-29 cells after 3 days by [3H]thymidine incorporation assay	[PMID: 20627379]
MCF7	IC₅₀	65 3 Compound: Pterostlibene	Cytotoxicity against human MCF7 cells measured 24 hrs by MTT assay Cytotoxicity against human MCF7 cells measured 24 hrs by MTT assay	[PMID: 27598238]
U-87MG ATCC	IC₅₀	34 3 Compound: Pter	Cytotoxicity against human U87 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human U87 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
HT-29	IC₅₀	28 3 Compound: Pter	Cytotoxicity against human HT-29 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human HT-29 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
MDA-MB-231	IC₅₀	63 3 Compound: Pter	Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
MDA-MB-231	IC₅₀	31.17 3 Compound: PTE	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 34043359]
HT-29	IC₅₀	> 60 3 Compound: 2	Cytotoxicity against human HT-29 cells assessed as inhibition of cell growth after 24 hrs by MTT assay Cytotoxicity against human HT-29 cells assessed as inhibition of cell growth after 24 hrs by MTT assay	[PMID: 26204233]
MDA-MB-231	IC₅₀	10 3 Compound: 2	Inhibitory concentration required for antiproliferative activity against human MDA-MB-231 cells Inhibitory concentration required for antiproliferative activity against human MDA-MB-231 cells	[PMID: 16250636]
HeLa	IC₅₀	9.43 3 Compound: 6	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay Cytotoxicity against human HeLa cells after 72 hrs by MTT assay	[PMID: 19689125]
J774	IC₅₀	10.5 3 Compound: 4	Antiinflammatory activity in mouse J774 cells assessed as reduction in LPS-induced MCP1 expression after 24 hrs by ELISA Antiinflammatory activity in mouse J774 cells assessed as reduction in LPS-induced MCP1 expression after 24 hrs by ELISA	[PMID: 29726680]
MDR	IC₅₀	42 3 Compound: 2a, pterostilbene	Antiproliferative activity against MDR human HL60R cell line Antiproliferative activity against MDR human HL60R cell line	[PMID: 16686543]
J774	IC₅₀	16.7 3 Compound: 4	Antiinflammatory activity in mouse J774 cells assessed as reduction in LPS-induced nitric oxide production after 24 hrs by Griess assay Antiinflammatory activity in mouse J774 cells assessed as reduction in LPS-induced nitric oxide production after 24 hrs by Griess assay	[PMID: 29726680]
NCI-H460	GI₅₀	2.7 6 Compound: 14d	In vitro growth inhibition of NCI-H460 (human non-small cell lung carcinoma) cell line. In vitro growth inhibition of NCI-H460 (human non-small cell lung carcinoma) cell line.	[PMID: 12036362]
NCI-H460	IC₅₀	17 3 Compound: Pter	Cytotoxicity against human NCI-H460 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human NCI-H460 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
J774	IC₅₀	8.7 3 Compound: 4	Antiinflammatory activity in mouse J774 cells assessed as reduction in LPS-induced IL6 expression after 24 hrs by ELISA Antiinflammatory activity in mouse J774 cells assessed as reduction in LPS-induced IL6 expression after 24 hrs by ELISA	[PMID: 29726680]
NIH3T3	IC₅₀	12.19 87 Compound: 21	Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay	[PMID: 22749392]
NIH3T3	IC₅₀	12.2 3 Compound: 16	Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by sulforhodamine-B colorimetric assay Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by sulforhodamine-B colorimetric assay	[PMID: 21803587]
K562	IC₅₀	10 3 Compound: 2a, pterostilbene	Antiproliferative activity against human K562 cell line expressing Bcr-Abl Antiproliferative activity against human K562 cell line expressing Bcr-Abl	[PMID: 16686543]
KM-20L2	GI₅₀	3.4 6 Compound: 14d	In vitro growth inhibition of KM20L2 cell line. In vitro growth inhibition of KM20L2 cell line.	[PMID: 12036362]
P388	ED₅₀	4.87 6 Compound: 14d	In vitro inhibition of P388 (murine leukemia) cell proliferation. In vitro inhibition of P388 (murine leukemia) cell proliferation.	[PMID: 12036362]
L02	IC₅₀	> 100 3 Compound: Pter	Cytotoxicity against human L-02 cells incubated for 24 hrs by MTT assay Cytotoxicity against human L-02 cells incubated for 24 hrs by MTT assay	[PMID: 34506712]
PANC-1	IC₅₀	50 3 Compound: Pter	Cytotoxicity against human PANC1 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human PANC1 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
RAW264.7	IC₅₀	30 3 Compound: 1b	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS/IFNgamma-induced NO production by measuring NO level preincubated for 2 hrs and followed by LPS/IFNgamma addition and measured after 24 hrs by Griess assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS/IFNgamma-induced NO production by measuring NO level preincubated for 2 hrs and followed by LPS/IFNgamma addition and measured after 24 hrs by Griess assay	[PMID: 31350127]
SK-MEL-2	IC₅₀	17 3 Compound: Pter	Cytotoxicity against human SK-MEL-2 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human SK-MEL-2 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
LN-229	IC₅₀	14 3 Compound: Pter	Cytotoxicity against human LN229 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human LN229 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
T47D	IC₅₀	35 3 Compound: Pter	Cytotoxicity against human T47D cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human T47D cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
U-87MG ATCC	IC₅₀	34 3 Compound: Pter	Cytotoxicity against human U87 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human U87 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
MCF7	GI₅₀	2.3 6 Compound: 14d	Cell growth inhibition of breast MCF-7 cells, expressed as 50% reduction in the net protein increase Cell growth inhibition of breast MCF-7 cells, expressed as 50% reduction in the net protein increase	[PMID: 12036362]
MCF7	IC₅₀	14.11 3 Compound: 21	Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay	[PMID: 22749392]
MCF7	IC₅₀	65 3 Compound: Pterostlibene	Cytotoxicity against human MCF7 cells measured 24 hrs by MTT assay Cytotoxicity against human MCF7 cells measured 24 hrs by MTT assay	[PMID: 27598238]
MDA-MB-231	IC₅₀	10 3 Compound: 2	Inhibitory concentration required for antiproliferative activity against human MDA-MB-231 cells Inhibitory concentration required for antiproliferative activity against human MDA-MB-231 cells	[PMID: 16250636]
MDA-MB-231	IC₅₀	31.17 3 Compound: PTE	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 34043359]
MDA-MB-231	IC₅₀	31.17 3 Compound: PTE	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay	[PMID: 38964169]
MDA-MB-231	IC₅₀	63 3 Compound: Pter	Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
MDR	IC₅₀	42 3 Compound: 2a, pterostilbene	Antiproliferative activity against MDR human HL60R cell line Antiproliferative activity against MDR human HL60R cell line	[PMID: 16686543]
NCI-H460	GI₅₀	2.7 6 Compound: 14d	In vitro growth inhibition of NCI-H460 (human non-small cell lung carcinoma) cell line. In vitro growth inhibition of NCI-H460 (human non-small cell lung carcinoma) cell line.	[PMID: 12036362]
NCI-H460	IC₅₀	17 3 Compound: Pter	Cytotoxicity against human NCI-H460 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human NCI-H460 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
NIH3T3	IC₅₀	12.19 3 Compound: 21	Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay	[PMID: 22749392]
NIH3T3	IC₅₀	12.2 3 Compound: 16	Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by sulforhodamine-B colorimetric assay Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by sulforhodamine-B colorimetric assay	[PMID: 21803587]
P388	ED₅₀	4.87 6 Compound: 14d	In vitro inhibition of P388 (murine leukemia) cell proliferation. In vitro inhibition of P388 (murine leukemia) cell proliferation.	[PMID: 12036362]
PANC-1	IC₅₀	50 3 Compound: Pter	Cytotoxicity against human PANC1 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human PANC1 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
RAW264.7	IC₅₀	30 3 Compound: 1b	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS/IFNgamma-induced NO production by measuring NO level preincubated for 2 hrs and followed by LPS/IFNgamma addition and measured after 24 hrs by Griess assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS/IFNgamma-induced NO production by measuring NO level preincubated for 2 hrs and followed by LPS/IFNgamma addition and measured after 24 hrs by Griess assay	[PMID: 31350127]
SK-MEL-2	IC₅₀	17 3 Compound: Pter	Cytotoxicity against human SK-MEL-2 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human SK-MEL-2 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
T47D	IC₅₀	35 3 Compound: Pter	Cytotoxicity against human T47D cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human T47D cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
U-87MG ATCC	IC₅₀	34 3 Compound: Pter	Cytotoxicity against human U87 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human U87 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]

In Vitro

Pterostilbene (0, 5, 25, 50, 100, 200 and 400 μM) shows inhibitory activity against the growth of HeLa cells, with IC₅₀s of 101.2 μM and 65.9 μM at 24 and 48 hrs, respectively. Ipterostilbene (0, 25, 100 and 200 μM) also induces the apoptosis HeLa cells^[2].
Pterostilbene (0.05, 0.1, 0.15 and 0.2 mM) has high anti-oxidant activity against DPPH, ABTS, hydroxyl, superoxide, hydrogen peroxide in a dose-dependent manner. Pterostilbene decreases lipid peroxides and hydroperoxides, reduces protein carbonyl groups and restores protein sulphydryl groups in response to damage by TBHP and As-Fe²⁺. Pterostilbene also inhibits single strand breaks in pBR322^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Pterostilbene (30 mg/kg daily, p.o. for 21 days) inhibits reactive oxygen species production in the animal model of inflammation^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Essai clinique

Masse moléculaire

256.30

Formule

C₁₆H₁₆O₃

CAS No.

537-42-8

Appearance

Solid

Color

White to off-white

SMILES

OC1=CC=C(/C=C/C2=CC(OC)=CC(OC)=C2)C=C1

Structure Classification

Stilbenes

Initial Source

Livraison

Room temperature in continental US; may vary elsewhere.

Stockage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Solvant et solubilité

In Vitro:

DMSO : 110 mg/mL (429.18 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.9017 mL	19.5084 mL	39.0168 mL
5 mM	0.7803 mL	3.9017 mL	7.8034 mL
10 mM	0.3902 mL	1.9508 mL	3.9017 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Calculateur de molarité
Calculateur de dilution

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 3.93 mg/mL (15.33 mM); Clear solution

This protocol yields a clear solution of ≥ 3.93 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (39.3 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.75 mg/mL (10.73 mM); Clear solution

This protocol yields a clear solution of ≥ 2.75 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (27.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.75 mg/mL (10.73 mM); Clear solution

This protocol yields a clear solution of ≥ 2.75 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (27.5 mg/mL) to 900 μL Corn oil, and mix evenly.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 15% Cremophor EL 85% Saline
Solubility: 3.33 mg/mL (12.99 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Pureté et documentation

Purity: 99.89%

Select Batch:

Fiche technique (273 KB) SDS (620 KB)

COA (245 KB) LCMS (98 KB)

Instruction de manipulation (2659 KB)

Références

[1]. McCormack D, et al. A review of pterostilbene antioxidant activity and disease modification. Oxid Med Cell Longev. 2013;2013:575482. [Content Brief]

[2]. Hong Bin W, et al. Pterostilbene (3',5'-dimethoxy-resveratrol) exerts potent antitumor effects in HeLa human cervical cancer cells via disruption of mitochondrial membrane potential, apoptosis induction and targeting m-TOR/PI3K/Akt signalling pathway. J BUON. 2018 Sep-Oct;23(5):1384-1389. [Content Brief]

[3]. Perecko T, et al. The effects of pterostilbene on neutrophil activity in experimental model of arthritis. Biomed Res Int. 2013;2013:106041. [Content Brief]

[4]. Acharya JD, et al. Protective effect of Pterostilbene against free radical mediated oxidative damage. BMC Complement Altern Med. 2013 Sep 26;13:238. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	3.9017 mL	19.5084 mL	39.0168 mL	97.5419 mL
	5 mM	0.7803 mL	3.9017 mL	7.8034 mL	19.5084 mL
	10 mM	0.3902 mL	1.9508 mL	3.9017 mL	9.7542 mL
	15 mM	0.2601 mL	1.3006 mL	2.6011 mL	6.5028 mL
	20 mM	0.1951 mL	0.9754 mL	1.9508 mL	4.8771 mL
	25 mM	0.1561 mL	0.7803 mL	1.5607 mL	3.9017 mL
	30 mM	0.1301 mL	0.6503 mL	1.3006 mL	3.2514 mL
	40 mM	0.0975 mL	0.4877 mL	0.9754 mL	2.4385 mL
	50 mM	0.0780 mL	0.3902 mL	0.7803 mL	1.9508 mL
	60 mM	0.0650 mL	0.3251 mL	0.6503 mL	1.6257 mL
	80 mM	0.0488 mL	0.2439 mL	0.4877 mL	1.2193 mL
	100 mM	0.0390 mL	0.1951 mL	0.3902 mL	0.9754 mL

Pterostilbene Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Pterostilbene537-42-8AutophagyInhibitorinhibitorinhibit

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Nom du produit			Requested Quantity *
Nom du demandeur *			Civilité
Adresse e-mail *			Numéro de téléphone *
Department			Nom de l'organisation *
City			État
Country or Region *
Remarques

Nom du produit			Lot #
Nom du demandeur *			Adresse e-mail *
Numéro de téléphone			Department *
Nom de l'organisation *			Country or Region *
Remarques

Nom
Email *

	Sorry, but the email address you supplied was invalid.

Pterostilbene

Avis client

Other Forms of Pterostilbene:

Pterostilbene Related Antibodies

10 Publications Citing Use of MCE Pterostilbene

Recommandations en vedette

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Activité biologique

Pureté et documentation

Références

Avis client

Pterostilbene Related Antibodies

Calculateur de molarité

Calculateur de dilution

Complete Stock Solution Preparation Table

Pterostilbene Related Classifications

Keywords:

Vos produits récemment consultés:

Avis client

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report